Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 732-737 , November 2007

Quality of Life and Prognosis in Heart Failure: Results of the Beta-Blocker Evaluation of Survival Trial (BEST)

Received 18 September 2006 ,Revised 24 May 2007 ,Accepted 6 July 2007.

References 

  1. Calman KC. Quality of life in cancer patients an hypothesis. J Med Ethics. 1984;10:124–127
  2. Cella DF, Tulsky DS. Measuring quality of life today: methodological aspects. Oncology. 1990;4:29–38
  3. Bowling A. What things are important in people's lives? A survey of the public's judgments to inform scales of health related quality of life. Soc Sci Med. 1995;41:1447–1462
  4. Heart Failure Guideline Panel. Heart failure: evaluation and care of patients with left ventricular dysfunction. AHCPR Publication No. 94–0612; 1994.
  5. Konstam V, Salem D, Pouleur H, Kostis J, Gorkin L, Shumaker S, et al. Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. Am J Cardiol. 1996;78:890–895
  6. Soto GE, Jones P, Weintraub WS, Krumholz HM, Spertus JA. Prognostic value of health status in patients with heart failure after acute myocardial infarction. Circulation. 2004;110:546–551
  7. Berry C, McMurray J. A review of quality-of-life evaluations in patients with congestive heart failure. Pharmacoeconomics. 1999;16:247–271
  8. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  9. Rector TS, Johnson G, Dunkman WB. Evaluation by patients with heart failure of the effects of Enalapril compared with hydralazine plus isosorbide dinitrate on quality of life. Circulation. 1993;8(Suppl VI):171–176
  10. Kubo SH, Gollub S, Bourge R, Rahko P, Cobb F, Jessup M, et al. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure: results of a multicenter trial. Circulation. 1992;85:942–949
  11. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, et al. The US Carvedilol Heart Failure Group. Safety and efficacy of carvedilol in severe heart failure. J Card Fail. 1997;3:173–179
  12. Green PC, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy questionnaire: a new health status measure for heart failure. J Am Coll Cardiol. 2000;35:1245–1255
  13. Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure: content, reliability, and validity of a new measure: The Minnesota Living with Heart Failure questionnaire. Heart Failure. 1987;3:198–219
  14. Hak T, Willems D, Van der Wal G, Visser F. A qualitative validation of the Minnesota Living with Heart Failure questionnaire. Qual Life Res. 2004;13:417–426
  15. The Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001;344:1659–1667
  16. Shabetai R. Cardiomyopathy: how far have we come in 25 years, how far yet to go?. J Am Coll Cardiol. 1983;1:252–263
  17. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation. 1996;94:2800–2806
  18. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, et al. Congestive heart failure/myocardial disease: carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807–2816
  19. Rector TS, Cohn JN. Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: reliability and validity during a randomized, double-blind, placebo-controlled trial of pimobendan. Pimobendan Multicenter Research Group. Am Heart J. 1992;124:1017–1025
  20. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol. 1993;71:1106–1107
  21. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–1302
  22. Rogers WJ, Johnstone DE, Yusuf S, Weiner DH, Gallagher P, Bittner VA, et al. Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. J Am Coll Cardiol. 1994;23:393–400
  23. Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, et al. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation. 1996;94:2793–2799
  24. Packer M, Fowler MF, Roecker EB, Coats AJ, Katus HA, Krum H, et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure Results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Circulation. 2002;106:2194–2199
  25. Anonymous. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–2007
  26. Wiklund I, Waagstein F, Swedberg K, Hjalmarsson A. Quality of life on treatment with metoprolol in dilated cardiomyopathy: results from the MDC trial. Metoprolol in Dilated Cardiomyopathy trial. Cardiovasc Drugs Ther. 1996;10:361–368
  27. Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet. 1993;342:1441–1446
  28. American Heart Association . 2002 heart and stroke statistical update. Dallas, TX: American Heart Association; 2001;
  29. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, et al. Cardiac resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350:2140–2150

 Dr. Lowes is supported by K23 HL068875.

PII: S1071-9164(07)00958-X

doi: 10.1016/j.cardfail.2007.07.001

Journal of Cardiac Failure
Volume 13, Issue 9 , Pages 732-737 , November 2007

Article Tools

* Image Usage & Resolution